SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Sugar Ray Robinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSugar Ray Robinson
Date of birth1921-05-03
IdentifiersMRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318
Document date1984-07-21
AuthorLangston Pryce-Okonjo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of memory loss, seen the same day by cognitive neurology. [S]

History of Present Illness

Sugar Ray Robinson returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Kowalski at the memory clinic. He had a brain MRI and a hearing test this morning. His intake blood count, kidney function, B12 and TSH were normal; hemoglobin A1c was 6.4%. He has slept well since stopping the over-the-counter sleep aid. He has not driven since intake; his care partner drives. The handgun stays unloaded and locked with the key held by his care partner. He repeated one question twice during the visit and laughed about it. [S]

ElementDetail
MMSE22
CDRGlobal 1, sum of boxes 5.5
MRIHippocampal atrophy; six microbleeds; no superficial siderosis; cavum septi pellucidi
AudiometryMild to moderate bilateral high-frequency hearing loss
SleepSleeping well without diphenhydramine

Review of Systems

SystemResultFinding
NeurologicalPositiveMemory loss; no headaches, weakness, tremor, falls or change in walking
PsychiatricNegativeNo low mood, hallucinations, suspiciousness or irritability
Ears, nose, mouth, and throatPositiveAsks people to repeat themselves in noisy rooms
EndocrineNegativeNo low glucose spells he or his care partner has noticed

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route1982-03-01activeS
Glipizide 5 mg oral tablet, one tablet before breakfastOne tablet before breakfastOral route1983-01-15 to 1984-08-18completedS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1981-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1982-03-01activeS
Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counterOne capsule at bedtimeOral route1983-10-01 to 1984-07-07stoppedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1984-07-21Body height180cmS
1984-07-21Body weight76.8kgS
1984-07-21Body mass index (BMI) [Ratio]23.7kg/m2S
1984-07-21Systolic blood pressure128mm[Hg]S
1984-07-21Diastolic blood pressure78mm[Hg]S
1984-07-21Heart rate70/minS
1984-07-21Respiratory rate14/minS
1984-07-21Body temperature36.6CelS
1984-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1984-07-21Mini-Mental State Examination [MMSE]22{score}S
1984-07-21Clinical Dementia Rating scale [CDR]1{score}S

Physical Exam

Vital signs recorded on 1984-07-21; see the Vital Signs section. [S]

SystemFinding
GeneralWell and cheerful; blood pressure 128/78; pulse 70; weight 76.8 kg
NeurologicalCranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; steady narrow-based gait; no dysarthria
Mental statusAlert and courteous; repeats questions; mood good; no psychotic symptoms

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be foundactiveconfirmed R41.3S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylureaactiveconfirmed E11.9S — Synthetic modern diabetes anchored to his documented diabetes.
Hypertension, controlled on lisinoprilactiveconfirmed I10S — Synthetic modern hypertension anchored to the single press report.
Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometryactiveconfirmed H90.3S — Synthetic finding checked as a modifiable contributor to cognitive difficulty.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCognitive testing (MoCA, MMSE)At diagnosis, then yearly, or sooner with changeCompleted todayMoCA 18 at intake; MMSE 22 today
SurveyDementia staging (CDR) and function (ADL and IADL)At diagnosis, then yearlyCompleted todayGlobal CDR 1 (sum of boxes 5.5); independent in personal care, needs help with bills, medicines and appointments (Functional Activities Questionnaire 11)
LaboratoryReversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearingOnce at diagnosisCompleted todayBlood count, metabolic panel, B12 352 pg/mL and TSH 1.9 at intake, normal; PHQ-9 4; diphenhydramine stopped; STOP-Bang 2 (low risk of sleep apnea); hearing loss on audiometry today
ImagingBrain MRIOnce at diagnosis; repeat only with an acute changeCompleted todayModerate hippocampal atrophy; six microbleeds; no siderosis or infarct; cavum septi pellucidi
ImagingAmyloid biomarker confirmation (PET or CSF)Once, when it will change diagnosis or treatmentOrderedAmyloid PET booked in two weeks
Medication safetyAnti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI scheduleAt diagnosis of MCI or mild dementia due to Alzheimer's diseaseNot indicatedNot a candidate: more than four cerebral microbleeds exclude lecanemab and donanemab under both appropriate use recommendations; APOE genotyping therefore not needed for treatment and offered only with counseling (declined); no ARIA monitoring schedule
Medication safetyMedicine review for anticholinergic and sedating drugs (Beers)Every visitCompleted todayDiphenhydramine stopped at intake; no other anticholinergic or sedating drugs
SurveyBehavioral and psychological symptoms (NPI-Q items)Every visitCompleted todayNone: no agitation, apathy, low mood, anxiety, hallucinations, delusions or sleep disturbance
Medication safetyCholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulseEach follow-up and each dose changeNot indicatedNot started until the cause is confirmed
Self-managementDriving, firearm and home safetyAt diagnosis and each follow-upCompleted todayNot driving; handgun unloaded and locked with the key held by his care partner; no wandering
Self-managementCare partner support and burden (Zarit, narrative)At diagnosis, then at least yearlyDueAt the diagnosis visit
Self-managementAdvance care planningAt diagnosis; revisit yearly and at changesDuePlanned at the preventive visit
LaboratoryHemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia reviewEvery three months after a therapy change; every six months when stableUp to date6.4% at intake; no low readings
ExaminationBlood pressure, goal under 130/80 mmHgEvery visitCompleted today128/78 mmHg on lisinopril
LaboratoryPotassium and creatinine on lisinopril and metforminYearly, and after acute illness or dehydrationUp to datePotassium 4.4 mmol/L, creatinine 1.0 mg/dL at intake
ExaminationDilated diabetic eye examinationEvery one to two years without retinopathyReferredRequested at intake; appointment pending
ReferralCognitive neurology consultationAt diagnosisCompleted todaySeen by Dr. Haddad-Kowalski today

Goal progress:

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Practice Parameter update: Evaluation and management of driving risk in dementia (2010)

Follow-up: Amyloid PET in two weeks. Six-week review for results, with his care partner. Hearing aid assessment. Call with any new confusion, falls or low glucose readings. Next scheduled visit 1984-08-18: six-week review: amyloid PET result, the diagnosis and the plan, with diabetes, driving, firearm and caregiver support. [S]